HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

combotox

a 50:50 mixture of two ricin-conjugated antibodies, RFB4 and HD37; has antineoplastic activity

Networked: 8 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schindler, John: 3 articles (10/2012 - 12/2009)
2.	Barta, Stefan K: 2 articles (03/2013 - 10/2012)
3.	Verma, Amit: 2 articles (10/2012 - 08/2011)
4.	Ghetie, Victor: 2 articles (08/2011 - 12/2009)
5.	Vitetta, E S: 2 articles (05/2000 - 04/2000)
6.	Groll, Andreas H: 1 article (03/2021)
7.	Kyriakidis, Ioannis: 1 article (03/2021)
8.	Roilides, Emmanuel: 1 article (03/2021)
9.	Rossig, Claudia: 1 article (03/2021)
10.	Tragiannidis, Athanasios: 1 article (03/2021)

Related Diseases

1.	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 08/01/2011 - "Pre-clinical data demonstrated that Combotox was effective in killing both pre-B-ALL cell lines and cells from patients with pre-B ALL. " 12/01/2009 - "Preclinical data have demonstrated which Combotox is effective in killing pre-B-ALL cell lines and cells from patients with pre-B ALL. " 05/01/2000 - "Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. "
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/01/2009 - "A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia." 10/01/2012 - "Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 04/01/2000 - "A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma." 04/01/2000 - "This study used an 8-day continuous infusion regimen of a 1:1 mixture of two immunotoxins (ITs) prepared from deglycosylated ricin A chain (dgA) conjugated to monoclonal antibodies directed against CD22 (RFB4-dgA) and CD19 (HD37-dgA; Combotox) in a Phase I trial involving 22 patients with refractory B cell lymphoma to determine the maximum tolerated dose, clinical pharmacology, and toxicity profile and to characterize any clinical responses. "
4.	Bites and Stings (Sting) 02/01/2015 - "In this review, we will focus on the clinical application of such therapies in adult ALL, including the naked antibodies: Rituximab, Ofatumumab, Epratuzumab and Alemtuzumab; the immunotoxins: BL22 and Combotox; the immunoconjugates: inotuzumab and SAR 3419; as well as the Bi-specific T cell engaging (BiTE)-specific antibody, Blinatumomab. " 03/05/2021 - "A detailed literature review until January 2021 was conducted regarding pediatric patient populations treated with agents that target CD2 (alefacept), CD3 (bispecific T-cell engager [BiTE] blinatumomab), CD19 (denintuzumab mafodotin, B43, BiTEs blinatumomab and DT2219ARL, the immunotoxin combotox, and chimeric antigen receptor [CAR] T-cell therapies tisagenlecleucel and axicabtagene ciloleucel), CD20 (rituximab and biosimilars, 90Y-ibritumomab tiuxetan, ofatumumab, and obinutuzumab), CD22 (epratuzumab, inotuzumab ozogamicin, moxetumomab pasudotox, BiTE DT2219ARL, and the immunotoxin combotox), CD25 (basiliximab and inolimomab), CD30 (brentuximab vedotin and iratumumab), CD33 (gemtuzumab ozogamicin), CD38 (daratumumab and isatuximab), CD52 (alemtuzumab), CD66b (90Y-labelled BW 250/183), CD248 (ontuxizumab) and immune checkpoint inhibitors against CTLA-4 (CD152; abatacept, ipilimumab and tremelimumab) or with PD-1/PD-L1 blockade (CD279/CD274; atezolizumab, avelumab, camrelizumab, durvalumab, nivolumab and pembrolizumab). "
5.	Neoplasms (Cancer) 03/01/2013 - "Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. "

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	Ricin
3.	Monoclonal Antibodies
4.	Inotuzumab Ozogamicin
5.	Alemtuzumab (Campath)
6.	Rituximab (Mabthera)
7.	immunotoxin HA22
8.	ofatumumab
9.	blinatumomab
10.	epratuzumab

Related Therapies and Procedures

1.	Therapeutics